Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial) (ImmunoProst)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03040791
Recruitment Status : Recruiting
First Posted : February 2, 2017
Last Update Posted : July 31, 2018
Bristol-Myers Squibb
Information provided by (Responsible Party):
Hospital Moinhos de Vento

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 1, 2019
Estimated Study Completion Date : July 1, 2019